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Teratocarcinoma and Embryonic Cell Interactions.
(Eds. T. MURAMATSU, G. GACHELIN, A. A.
MOSCONA and Y. IKAWA) UK, Academic Press,
Inc, 344 pp, 1982, £23.80.
We are living in the golden age of molecular and
cellular biology. New discoveries assail us from the
pages of "learned" journals and are often published
first in the daily newspapers. At such a time two
years is a long period to wait for a meeting report
which summarises an area of active research. The
editors have attempted to ameliorate this problem
by writing a summary of the advances made in
teratocarcinoma research between 1980 and the
publication date. Unfortunately, this serves to
emphasise the problem and increases the
introduction section of the book to the record
proportions of two Forewords, a Preface and two
Editorial Notes.
Teratocarcinomas are a focal point where tumour
biology and developmental biology meet. This
confluence has contributed much to concepts in
tumour biology and is currently apparent in the
study of high molecular weight carbohydrate
structures found on murine embryos and
teratocarcinoma stem cells and on many human
tumour cells. The clustering of related papers on
the same topic is one of the advantages that a
meeting report has compared with conventional
publication and the editors are to be congratulated
on their prescience in selecting carbohydrate
biochemistry as a major theme of their meeting.
Another advantage the meeting report has over
journal publication is the possibility of including
discussion of presented papers. These sections in
the book make exciting reading being, apparently,
faithful transcripts even down to the theatrical
gestures of the speakers. In conclusion, this book,
by its very nature, is dated in content and nearly all
the work is published elsewhere; this disadvantage
is partially offset by being a convenient, single
volume, summary of the teratocarcinoma story as it
was in 1980.
P.N. Goodfellow
Imperial Cancer Research Fund Laboratories,
Lincoln's Inn Fields,
London WC2
Mutagenicity-New Horizons in Genetic Toxicology.
(Ed. J. A. HEDDLE) UK, Academic Press Inc., 471
pp, 1982, £36.40.
This is a rather expensive collection of 16 chapters
intended to illustrate the very wide range of
problems which can be tackled by applying short-
term mutagenicity tests. The book starts with
microbial tests, follows with chapters on cultured
mammalian cells, tests based on sampling cells from
human populations, and ends with two chapters on
monitoring environmental pollution using higher
plants and fish as indicators of genetic damage.
The selection of subject matter is rather quirky.
There are two chapters on the use and relevance of
short-term tests for detecting mutagens in food
(Sugimura and Nago; Stich, et al.) but nothing on
the use of mutagenicity tests for looking for
endogenous mutagens in body fluids and excreta-
surely a "new horizon" and fascinating if only for
the enormous problems attendant upon such
studies. A chapter on the use of short-term tests for
monitoring water supplies is also lacking.
The book starts with John Ashby's stimulating
views on the value of short-term tests for predicting
long-term effects such as carcinogenicity. In the
preface, the Editor (John Heddle) alludes to the
"explosive growth" in this area, and in one respect,
Ashby has been caught in the blast. He dwells upon
the challenge to genotoxicology posed by the
inability of ethylene oxide (a potent, directly-acting
alkylating mutagen) to induce tumours at the site
of application-the respiratory tract of animals
dosed by inhalation. This is an unusual finding for
a directly-acting alkylating agent. He makes much
of tumours (testicular mesotheliomas) which arose
remote from the application site, and suggests that
the bacterial mutagenicity of ethylene oxide resides
in the activity of the parent molecule, and that the
"indirect" carcinogenic effect in mammals may be
due to a metabolite: this may be so. However, like
the unfortunate Richard III, Ashby runs before his
horse to market, since ethylene oxide does induce
tumours at the site of application. Dunkelberg (Br.
J. Cancer, 46: 924, 1982) force-fed rats with it and
produced squamous-cell carcinomas of the fore-
stomach. Even after 3 years, this treatment did not
induce tumours remote from the application site.
This illustrates the dangers of over-interpreting
short-term data (which are easy to collect and
therefore plentiful) and using them to erect
elaborate hypotheses to explain scarce and
sometimes dubious data from long-term
experiments. However, Ashby has done us a service
by airing these problems.
There follows a useful chapter by Bartsch,
Tomatis and Malaveille, who have exploited the
valuable resources of the IARC to produce some
excellent summaries relating Ames-test data on
selected carcinogens to the Covalent Binding Index
of Lutz. They discuss in some depth the possibility736 BOOK REVIEWS
that there may be a useful quantitative relationship
between short-term mutagenicity data and long-
term carcinogenicity data. Not surprisingly, they
conclude that such a relationship is unlikely (at
least that is how I interpreted their guarded
conclusions).
There is an excellent chapter by Carrano and
Moore on methods for quantifying sister-chromatid
exchange in humans. The authors supply some
valuable data which demonstrates the variability of
SCE levels in human peripheral lymphocytes and
emphasise the need for rigorous statistical design of
protocols.
Despite its uneven coverage, this volume will be a
very useful source of reference to anyone interested
in genetic toxicology, and does succeed in
demonstrating the versatility of short-term tests in
allowing investigations which would have been
impossible only one or two decades ago.
S. Venitt,
Institute for Cancer Research,
Pollards Wood Research Station,
Chalfont St. Giles, Bucks.
Prostaglandins and Cancer. (Prostaglandins and
Related Lipids-Vol. 2). (Eds. T. J. POWLES, R. S.
BOCKMAN, K. V. HONN and P. RAMWELL) New
York, Alan R. Liss Inc., 841 pp, 1982.
This book records the proceedings of the "First
International Conference on Prostaglandins and
Cancer" held in 1981 with the stated objective of
bringing together those scientists involved in
prostaglandin research, with those involved in
cancer research. These proceedings indicate that
this objective was fulfilled, although the bias is
towards the biology rather than the chemistry of
the prostaglandins.
It is divided into eight major sections. The first
comprises four review articles which provide an
excellent introduction to the metabolism and
pharmacology of the prostaglandins. The remaining
sections are each divided into review papers and
brief reports. Many of the latter are so insubstantial
as to only add to the bulk of an overlong book
without adding significantly to its value.
The second and third sections cover respectively,
the initiation and promotion phases of
carcinogenesis. The former provides in-depth
reviews on the role of prostaglandin oxygenases in
the synthesis of carcinogenic metabolites, whilst the
latter is concerned with the actual role that the
prostaglandins may play in tumour promotion.
The next two sections concern the role of
prostaglandins in the control of cell replica-
tion/proliferation and cell differentiation/inter-
action. These are followed by a section entitled
Prostaglandins, bone metastases and hypercalcaemia
which closely relates to the following section
covering host-tumour interactions. These two
sections attempt to integrate the relationship and
relative roles of prostaglandins synthesised by the
tumour cell and the host during tumour
progression.
The concluding section, covering the effect of
pharmacological manipulation of prostaglandin
synthesis on tumour growth and metastasis in vivo,
describes potential applications to the treatment of
cancer. The final paper in this section describes the
sole human study and concludes on the depressing
note that the infusion of prostaglandins known to
inhibit tumour cell proliferation in experimental
systems has no effect on the progression of human
cancer. This disappointing result is in contrast to
the work described elsewhere in this book, which
covers an exciting interaction between two areas of
scientific research.
Specialists in the field of prostaglandin research
will probably gain little from this book, but those
oncologists prepared to delve into its 841 pages will
find many papers of interest.
K. Moore,
CRC Medical Oncology Unit,
Southampton General Hospital,
Southampton
Pharmacologic Principles of Cancer Treatment. (Ed.
B. CHABNER) USA, W. B. Saunders Company, 457
pp, 1982, £45.00
Over the last five years there have been a number
of books dealing with the pharmacology of anti-
cancer drugs. Although these have been of interest
there has really been no authoritative volume that
has dealt with this subject in depth. This is the first
time I have had the opportunity to review such a
text and I feel that this will fill a real need for all
those concerned in oncology. The book is divided
into two sections, the first contains excellent
reviews on the principles of cell kinetics,
pharmacokinetics, clinical pharmacology and late
complications of drug therapy. The second section
is devoted to individual chapters on all the
commonly used cytotoxic agents. Each is
comprehensively covered and an authoritative
bibliography appended. Throughout,. the text
presents a unanimity that holds the reader's
attention, diagrams and tables are clearly labelled,
and not overdone. This book should appeal to all
those involved in the care of the patient with